Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH

Wei,Hongwei; Zhang,Dongqing; Liu,Lili; Xia,Wei; Li,Fuhai

doi:10.3892/etm.2018.6942

Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH

Authors:
- Hongwei Wei
- Dongqing Zhang
- Lili Liu
- Wei Xia
- Fuhai Li
View Affiliations

Affiliations: Department of Pediatrics, The Third Hospital of Jinan, Jinan, Shandong 250132, P.R. China, Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: November 8, 2018 https://doi.org/10.3892/etm.2018.6942
Pages: 71-78
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic protein (BMP) and Rho kinase signaling pathways exert counter regulatory effects on pulmonary artery smooth muscle cell (PASMC) proliferation in pulmonary artery hypertension (PAH). To elucidate the mechanism of this interaction, the present study tested whether Rho kinase activated by platelet derived growth factor‑BB (PDGF‑BB) enhances PASMC proliferation by suppressing the nuclear translocation of Smad1 induced by BMP‑2. BMP‑2 was used to activate the Smad1 signaling pathway and PDGF‑BB was used to activate the Rho kinase signaling pathway when cells were pretreated with or without Rho‑associated protein kinase (ROCK) inhibitor Y‑27632 or dual specificity mitogen‑activated protein kinase kinase (MEK) 1 and 2 inhibitor U0126. Western blotting was used to determine the expression of the components of the Rho signaling pathway, and the expression of various variants of phosphorylated mothers against decapentaplegic homolog (p‑Smad)1 in the cytoplasm and nucleus. Immunofluorescent staining was used to observe subcellular distribution of p‑Smad1. A cell counting kit was used to analyze cell proliferation. Active RhoA/Rho kinase signaling and decreased nuclear translocation of Smad1 were found in primary cultured PASMCs from the rat model of PAH compared with the control PASMCs. Treatment with BMP‑2 significantly increased nuclear accumulation of Smad1 and inhibited the proliferation of PASMCs. However, pretreatment with PDGF‑BB significantly decreased the nuclear accumulation of Smad1 induced by BMP‑2 and enhanced the proliferation of PASMCs. Furthermore, pretreatment with Y‑27632 or U0126 was found to restore the nuclear translocation of Smad1 suppressed by PDGF‑BB and decrease the proliferation of PASMCs. In conclusion, the present study suggested that Rho kinase activated by PDGF‑BB suppressed BMP‑2‑induced nuclear translocation of Smad1 via the MEK/mitogen‑activated protein kinase and enhanced BMP‑2‑inhibited proliferation of PASMCs.

View Figures

View References

1	Miyazono K, Kamiya Y and Morikawa M: Bone morphogenetic protein receptors and signal transduction. J Bio chem. 147:35–51. 2010.
2	Sieber C, Kopf J, Hiepen C and Knaus P: Recent advances in bmp receptor signaling. Cytokine Growth Factor Rev. 20:343–355. 2009. View Article : Google Scholar : PubMed/NCBI
3	Awad KS, West JD, de Jesus Perez V and MacLean M: Novel signaling pathways in pulmonary arterial hypertension. Pulm Circ. 6:285–294. 2015. View Article : Google Scholar
4	West J, Austin E, Fessel JP, Loyd J and Hamid R: Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. Drug Discov Today. 19:1241–1245. 2014. View Article : Google Scholar : PubMed/NCBI
5	Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH and Humbert M: Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardio. l62 25 Suppl:D13–D21. 2013. View Article : Google Scholar
6	Ormiston ML, Upton PD, Li W and Morrell NW: The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2015:472015. View Article : Google Scholar : PubMed/NCBI
7	Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, et al: Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 21:777–785. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yang J, Li X, Al-Lamki RS, Wu C, Weiss A, Berk J, Schermuly RT and Morrell NW: Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 33:34–42. 2013. View Article : Google Scholar : PubMed/NCBI
9	Price LC, Montani D, Tcherakian C, Dorfmüller P, Souza R, Gambaryan N, Chaumais MC, Shao DM, Simonneau G, Howard LS, et al: Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 37:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
10	Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH, Chung WK, Benjamin N, Elliott CG, Eyries M, et al: Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects. Hum Mutat. 36:1113–1127. 2015. View Article : Google Scholar : PubMed/NCBI
11	Upton PD and Morrell NW: The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol. 98:1262–1266. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wrana JL: Regulation of smad activity. Cell. 100:189–192. 2000. View Article : Google Scholar : PubMed/NCBI
13	Sapkota G, Alarcón C, Spagnoli FM, Brivanlou AH and Massagué J: Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell. 25:441–454. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kretzschmar M, Doody J and Massague J: Opposing bmp and egfsignalling pathways converge on the tgf-beta family mediator smad1. Nature. 389:618–622. 1997. View Article : Google Scholar : PubMed/NCBI
15	Wilson JL, Yu J, Taylor L and Polgar P: Hyperplastic growth of pulmonary artery smooth muscle cells from subjects with pulmonary arterial hypertension is activated through JNK and p38 MAPK. PLoS One. 10:e01236622015. View Article : Google Scholar : PubMed/NCBI
16	Jin C and Guo J, Qiu X, Ma K, Xiang M, Zhu X and Guo J: IGF-1 induces iNOS expression via the p38 MAPK signal pathway in the anti-apoptotic process in pulmonary artery smooth muscle cells during PAH. J Recept Signal Transduct Res. 34:325–331. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ziino AJ, Ivanovska J, Belcastro R, Kantores C, Xu EZ, Lau M, McNamara PJ, Tanswell AK and Jankov RP: Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. Pediatr Res. 67:177–182. 2010. View Article : Google Scholar : PubMed/NCBI
18	Yasuda T, Tada Y, Tanabe N, Tatsumi K and West J: Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol. 301:L667–L674. 2011. View Article : Google Scholar : PubMed/NCBI
19	Jasińska-Stroschein M, Owczarek J, Sołtysiak U and Orszulak-Michalak D: Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension. Arch Med Sci. 12:898–905. 2016. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Ren W, Warburton R, Toksoz D and Fanburg BL: Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J. 23:2299–2306. 2009. View Article : Google Scholar : PubMed/NCBI
21	Chen XY, Dun JN, Miao QF and Zhang YJ: Fasudil hydrochloride hydrate, a rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via jnk and erk1/2 pathway. Pharmacology. 83:67–79. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tanabe T, Furuya H, Kanemoto N, Goto Y and Hata J: Experimental study on monocrotaline induced pulmonary hypertensive rats. (1) Effect of long-term injection of immunosuppressant. Tokai J Exp Clin Med. 6:41–48. 1981.PubMed/NCBI
23	Li F, Xia W, Li A, Zhao C and Sun R: Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol Res. 55:64–71. 2007. View Article : Google Scholar : PubMed/NCBI
24	The Ministry of Science and Technology of the People's Republic of China: Guidance Suggestions for the Care and Use of Laboratory Animals. 2006.http://www.most.gov.cn/fggw/zfwj/zfwj2006/200609/t20060930_54389.htmSeptember 30–2006
25	Amano M, Nakayama M and Kaibuchi K: Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 67:545–554. 2010. View Article : Google Scholar : PubMed/NCBI
26	Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M and Ahsan F: Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release. 167:189–199. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xiao JW, Zhu XY, Wang QG, Zhang DZ, Cui CS, Zhang P, Chen HY and Meng LL: Acute effects of Rho-kinase inhibitor fasudilon pulmonary arterial hypertension in patients with congenital heart defects. Circ J. 79:1342–1348. 2015. View Article : Google Scholar : PubMed/NCBI
28	Jiang X, Wang YF, Zhao QH, Jiang R, Wu Y, Peng FH, Xu XQ, Wang L, He J and Jing ZC: Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study. Int J Cardiol. 77:61–65. 2014. View Article : Google Scholar
29	Luo L, Zheng W, Lian G, Chen H, Li L, Xu C and Xie L: Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway. Int J Mol Med. 41:51–60. 2018.PubMed/NCBI
30	Zhang Y, Lu W, Yang K, Xu L, Lai N, Tian L, Jiang Q, Duan X, Chen M and Wang J: Bone morphogenetic protein 2 decreases TRPC expression, store-operated Ca(2+) entry, and basal [Ca(2+)]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 304:C833–C843. 2013. View Article : Google Scholar : PubMed/NCBI
31	Watanabe H: Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J. 73:1597–1598. 2009. View Article : Google Scholar : PubMed/NCBI
32	Morrell NW: Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension. AdvExp Med Biol. 661:251–264. 2010. View Article : Google Scholar
33	Kamiyama M, Utsunomiya K, Taniguchi K, Yokota T, Kurata H, Tajima N and Kondo K: Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb. 10:117–123. 2003. View Article : Google Scholar : PubMed/NCBI
34	Nunes KP, Rigsby CS and Webb RC: Rhoa/rho-kinase and vascular diseases: What is the link? Cell Mol Life Sci. 67:3823–3836. 2010. View Article : Google Scholar : PubMed/NCBI